Parabilis Medicines, Inc. (PBLS) is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company that went public on the Nasdaq in June 2026. Its lead asset, zolucatetide, is a first-in-class inhibitor of the beta-catenin:TCF interaction in the Wnt signaling pathway, with lead indications in desmoid tumors, familial adenomatous polyposis (FAP), and hepatocellular carcinoma.
Seven current analyst price targets were reviewed, spanning roughly $39 to $45, with a calculated mean of about $41.29, rounded to a $41 central target. Ratings are uniformly bullish: BofA Securities initiated at Buy with a $45 target, while Guggenheim, Leerink Partners, and H.C. Wainwright each initiated with $40 targets. This narrow but above-market range reflects broad agreement on the platform's promise while acknowledging that valuation hinges on clinical execution rather than near-term earnings. Notably, no tracked analyst assigns a Hold or Sell rating. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The stock closed near $29.65, meaning the $41 target implies about 38% upside. That is a substantial move, though within the range the stock has already demonstrated: its 52-week range runs from $22.66 to $42.49. Because the shares peaked at $42.49 in September 2026, $41 sits just below that prior high rather than representing uncharted territory.
The path toward the target depends on continued positive clinical readouts. Zolucatetide has produced a reported 74% objective response rate (ORR) in desmoid tumor patients with at least two post-baseline scans, and updated data in late October 2026 showed a 72.2% ORR at week 32 with 100% disease control at doses of 450 mg or higher. A global registrational Phase 3 trial (PEDESTAL) is planned to begin in the first half of 2027, with top-line data targeted for 2029. The company held roughly $1.12 billion in cash against a market capitalization near $3.7 billion, providing a multi-year runway.
The $42.49 level, set in September 2026, is the clearest near-term reference point and sits just above the $41 target, making it a logical resistance zone. The $40 round-number level has served as both an analyst anchor and a psychological marker. On the downside, the October 2026 low near $22.66 and the June 2026 IPO price of $20.00 define durable support zones. A sustained move toward the target would likely require the stock to reclaim and hold the $36–$40 area, where it traded before pulling back in the autumn of 2026.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms do not always publish explicit timeframes. Investors should watch quarterly clinical updates on zolucatetide, the planned initiation of the Phase 3 PEDESTAL trial in desmoid tumors in the first half of 2027, additional data in FAP and hepatocellular carcinoma, cash-burn trends in each earnings report, and any analyst target revisions. Regulatory milestones and broader biotech financing conditions are also relevant to the market outlook.
For traders seeking a data-driven overlay, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. The tool helps traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening. Those interested in an algorithmic edge can explore the signals to complement their own research. I have found this approach useful when evaluating names like PBLS alongside traditional analysis.
Whether PBLS can reach $41 depends less on near-term earnings and more on sustained clinical momentum for zolucatetide. The $41 average analyst price target, drawn from seven targets spanning $39 to $45, sits just below the stock's 52-week high of $42.49, so it is not a stretch beyond levels already traded. A roughly 38% move would still be substantial, however, and rests on catalysts such as Phase 3 initiation, continued strong desmoid tumor data, and pipeline expansion. Against that, the company's lack of revenue, binary trial risk, and dilution potential are meaningful obstacles. Investors should weigh the uniformly bullish analyst consensus against the inherent uncertainty of clinical-stage development and monitor upcoming data readouts and cash-burn figures closely.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Stochastic Oscillator for PBLS moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 3 similar instances where the indicator exited the overbought zone. In 3 of the 3 cases the stock moved lower. This puts the odds of a downward move at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PBLS's RSI Oscillator exited the oversold zone, 1 of 1 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on PBLS as a result. In 2 of 4 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 50%.
Following a +8.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where PBLS advanced for three days, in 14 of 18 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
PBLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 10 of 11 cases where PBLS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The Tickeron PE Growth Rating for this company is 51 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. PBLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.364) is normal, around the industry mean (3.498). P/E Ratio (-15.212) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PBLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology